Liraglutide Combination Products Incorporating Stevanato Group's Alina® Pen Injector Receive European Marketing Authorizations
Key Insights
Liraglutide-based combination products using Stevanato Group (search)'s Alina® pen injector platform have received marketing authorizations across multiple European markets.
The approved configurations include Alina® 30 for diabetes (search) and Alina® 50 for weight management, both part of the variable-dose pen injector platform.
The Alina® platform features a dial-a-dose mechanism with visual, audible, and tactile feedback, compatible with ISO standard 3 mL glass cartridges.
Stevanato Group (search) S.p.A. (NYSE: STVN) announced that liraglutide-based combination products incorporating its proprietary Alina® pen injector platform have received marketing authorizations in Europe. The authorizations, held by the respective Marketing Authorization Holders, cover therapies for both diabetes (search) and weight management, marking a significant expansion in the commercial adoption of the company's drug delivery technology.
The approved configurations include Alina® 30, developed for liraglutide-based therapies targeting diabetes (search), and Alina® 50, designed specifically for liraglutide-based weight management applications. Both variants are part of Stevanato Group (search)'s broader Alina® variable-dose pen injector platform, which offers multiple pre-configured variants for GLP-1 (search) receptor agonists and other injectable therapies.
Device Design and Functionality
Alina® is a variable-dose, disposable pen injector platform engineered for subcutaneous drug delivery. The device accommodates doses ranging from 0.01 mL up to 0.75 mL and features a dial-a-dose mechanism that provides visual, audible, and tactile feedback during both dose selection and injection. The platform is compatible with ISO standard 3 mL glass cartridges and has been designed with manufacturing scalability in mind, supporting integration into existing pharmaceutical fill-and-finish and final assembly supply chains.
"We are pleased to see Alina® incorporated into liraglutide-based therapies that have received marketing authorizations in multiple European markets," said Michele Monico, President of Drug Delivery Systems & In Vitro Diagnostics at Stevanato Group (search). "This achievement highlights our commitment to support customers throughout their product journey, from development to commercialization."
Strategic Positioning in a Growing Market
The European authorizations arrive at a time when injectable therapies are playing an increasingly important role in healthcare, driven by the ongoing expansion of GLP-1 (search) treatments and a broader shift toward patient-centric models of care and self-administration. Monico emphasized the strategic significance of drug delivery systems in this evolving landscape: "The rapid growth of biologics, GLP-1 therapies, and self-administration is reshaping how pharmaceutical companies approach product development and commercialization. As a result, demand is increasing for integrated solutions that combine device innovation, manufacturing expertise, and supply chain reliability."
Stevanato Group (search)'s proprietary device portfolio now spans four platforms: Alina® (variable-dose pen injector), Deora™ (fixed-dose pen injector), Aidaptus® (autoinjector), and Vertiva® (on-body delivery system). Alina® is manufactured within the company's Drug Delivery Systems operations and leverages integrated expertise across pharmaceutical glass containers, engineering technologies, analytical services, and device manufacturing.
"As demand for treatments addressing diabetes (search) and weight management continues to grow, we are proud to provide drug delivery solutions that help enable broader patient access to these therapies," Monico added.
The platform has been designed to offer pharmaceutical partners a flexible and production-ready solution capable of supporting commercial-scale deployment, positioning Stevanato Group (search) to support the evolving needs of pharmaceutical and biotechnology companies developing next-generation injectable therapies.